Do analysts rate TCRX or CUE?

TScan Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 798.20%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

TScan Therapeutics (TCRX) Competitors

$0.67 -0.06 (-8.32%)

As of 12:08 PM Eastern

Compare

TCRX vs. CRBP, CHRS, CUE, LUCD, and KRRO

Should you buy TScan Therapeutics stock or one of its competitors? TScan Therapeutics's main competitors and comparable companies include Corbus Pharmaceuticals (CRBP), Coherus Oncology (CHRS), Cue Biopharma (CUE), Lucid Diagnostics (LUCD), and Korro Bio (KRRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TScan Therapeutics compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Corbus Pharmaceuticals currently has a consensus price target of $41.00, indicating a potential upside of 265.26%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 798.20%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Corbus Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Corbus Pharmaceuticals' return on equity of -87.05% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

In the previous week, Corbus Pharmaceuticals and Corbus Pharmaceuticals both had 1 articles in the media. TScan Therapeutics' average media sentiment score of 1.87 beat Corbus Pharmaceuticals' score of 0.93 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Positive
TScan Therapeutics	Very Positive

Corbus Pharmaceuticals has a beta of 2.59, meaning that its stock price is 159% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Corbus Pharmaceuticals has higher earnings, but lower revenue than TScan Therapeutics. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
TScan Therapeutics	$10.32M	4.39	-$129.77M	-$0.91	N/A

Summary

TScan Therapeutics beats Corbus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does TScan Therapeutics compare to Coherus Oncology?

TScan Therapeutics (NASDAQ:TCRX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

TScan Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Coherus Oncology has higher revenue and earnings than TScan Therapeutics. Coherus Oncology is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.39	-$129.77M	-$0.91	N/A
Coherus Oncology	$42.17M	5.07	$168.02M	-$1.03	N/A

In the previous week, Coherus Oncology had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 3 mentions for Coherus Oncology and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.87 beat Coherus Oncology's score of 0.98 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
Coherus Oncology	Positive

Coherus Oncology has a net margin of -259.41% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Coherus Oncology	-259.41%	-222.75%	-52.11%

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 7.2% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

TScan Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 798.20%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 525.75%. Given TScan Therapeutics' higher probable upside, research analysts plainly believe TScan Therapeutics is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

TScan Therapeutics and Coherus Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Cue Biopharma?

TScan Therapeutics (NASDAQ:TCRX) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Cue Biopharma had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Cue Biopharma and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.87 beat Cue Biopharma's score of 1.24 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
Cue Biopharma	Positive

TScan Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market.

Cue Biopharma has higher revenue and earnings than TScan Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.39	-$129.77M	-$0.91	N/A
Cue Biopharma	$27.47M	7.22	-$26.60M	-$27.02	N/A

Cue Biopharma has a net margin of -435.83% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Cue Biopharma	-435.83%	-620.06%	-291.15%

TScan Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 798.20%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

TScan Therapeutics beats Cue Biopharma on 9 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Lucid Diagnostics has a net margin of -959.76% compared to TScan Therapeutics' net margin of -1,655.35%. Lucid Diagnostics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 329.49%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 798.20%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Lucid Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lucid Diagnostics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Lucid Diagnostics has higher earnings, but lower revenue than TScan Therapeutics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	42.07	-$58.01M	-$0.47	N/A
TScan Therapeutics	$10.32M	4.39	-$129.77M	-$0.91	N/A

In the previous week, Lucid Diagnostics had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 3 mentions for Lucid Diagnostics and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.87 beat Lucid Diagnostics' score of 0.94 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lucid Diagnostics	Positive
TScan Therapeutics	Very Positive

Summary

Lucid Diagnostics beats TScan Therapeutics on 9 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

TScan Therapeutics has a net margin of -1,655.35% compared to Korro Bio's net margin of -1,834.48%. TScan Therapeutics' return on equity of -108.72% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

Korro Bio presently has a consensus target price of $16.71, suggesting a potential upside of 34.79%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 798.20%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Korro Bio has higher earnings, but lower revenue than TScan Therapeutics. Korro Bio is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	28.58	-$117.26M	-$10.00	N/A
TScan Therapeutics	$10.32M	4.39	-$129.77M	-$0.91	N/A

In the previous week, Korro Bio had 6 more articles in the media than TScan Therapeutics. MarketBeat recorded 7 mentions for Korro Bio and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.87 beat Korro Bio's score of 0.77 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Korro Bio	Positive
TScan Therapeutics	Very Positive

Korro Bio has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Summary

TScan Therapeutics beats Korro Bio on 10 of the 17 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$45.48M	$3.95B	$7.15B	$12.76B
Dividend Yield	N/A	3.61%	2.54%	10.96%
P/E Ratio	-0.74	11.84	272.37	25.17
Price / Sales	4.39	1,323.13	618.45	97.60
Price / Cash	N/A	44.06	28.78	36.03
Price / Book	0.31	16.86	11.04	6.27
Net Income	-$129.77M	-$22.72M	$3.47B	$348.97M
7 Day Performance	-15.84%	-2.55%	-1.52%	-1.95%
1 Month Performance	-10.09%	11.30%	7.32%	3.46%
1 Year Performance	-62.89%	54.55%	23.96%	14.18%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	3.5749 of 5 stars	$0.67 -8.5%	$6.00 +798.2%	-59.5%	$45.48M	$10.32M	N/A	100	Positive News
CRBP Corbus Pharmaceuticals	3.0823 of 5 stars	$11.19 +4.7%	$41.00 +266.4%	+16.4%	$208.82M	N/A	N/A	40	High Trading Volume
CHRS Coherus Oncology	2.0433 of 5 stars	$1.36 -0.4%	$8.67 +539.6%	+16.4%	$207.80M	$50.94M	N/A	330
CUE Cue Biopharma	1.0411 of 5 stars	$27.59 +19.0%	N/A	-96.4%	$203.14M	$27.47M	N/A	60	Positive News
LUCD Lucid Diagnostics	2.1951 of 5 stars	$0.99 -0.7%	$4.19 +321.7%	-22.3%	$201.82M	$5.45M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. CRBP, CHRS, CUE, LUCD, and KRRO

How does TScan Therapeutics compare to Corbus Pharmaceuticals?

Summary

How does TScan Therapeutics compare to Coherus Oncology?

Summary

How does TScan Therapeutics compare to Cue Biopharma?

Summary

How does TScan Therapeutics compare to Lucid Diagnostics?

Summary

How does TScan Therapeutics compare to Korro Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. CRBP, CHRS, CUE, LUCD, and KRRO

How does TScan Therapeutics compare to Corbus Pharmaceuticals?

Do institutionals and insiders believe in CRBP or TCRX?

Do analysts recommend CRBP or TCRX?

Is CRBP or TCRX more profitable?

Does the media prefer CRBP or TCRX?

Which has more volatility & risk, CRBP or TCRX?

Which has stronger valuation & earnings, CRBP or TCRX?

Summary

How does TScan Therapeutics compare to Coherus Oncology?

Which has more volatility and risk, TCRX or CHRS?

Which has better earnings and valuation, TCRX or CHRS?

Does the media favor TCRX or CHRS?

Is TCRX or CHRS more profitable?

Do institutionals & insiders have more ownership in TCRX or CHRS?

Do analysts recommend TCRX or CHRS?

Summary

How does TScan Therapeutics compare to Cue Biopharma?

Does the media refer more to TCRX or CUE?

Which has more volatility and risk, TCRX or CUE?

Which has stronger earnings & valuation, TCRX or CUE?

Is TCRX or CUE more profitable?

Do analysts rate TCRX or CUE?

Do insiders and institutionals have more ownership in TCRX or CUE?

Summary

How does TScan Therapeutics compare to Lucid Diagnostics?

Is LUCD or TCRX more profitable?

Do analysts recommend LUCD or TCRX?

Do insiders & institutionals have more ownership in LUCD or TCRX?

Which has more volatility & risk, LUCD or TCRX?

Which has preferable valuation & earnings, LUCD or TCRX?

Does the media refer more to LUCD or TCRX?

Summary

How does TScan Therapeutics compare to Korro Bio?

Is KRRO or TCRX more profitable?

Do analysts rate KRRO or TCRX?

Do insiders & institutionals hold more shares of KRRO or TCRX?

Which has stronger earnings & valuation, KRRO or TCRX?

Does the media favor KRRO or TCRX?

Which has more risk and volatility, KRRO or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools